Autolus Therapeutics plc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

AUTL$1.32+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of F-

Consolidated Balance Sheets

	December 31,
	Note	2023	2022
Assets
Current assets:
Cash and cash equivalents		$239,566	$382,436
Restricted cash		769	325
Prepaid expenses and other current assets	7	34,967	43,010
Total current assets		275,302	425,771
Non-current assets:
Property and equipment, net	8	34,862	35,209
Prepaid expenses and other non-current assets		380	2,176
Operating lease right-of-use assets, net	18	60,791	23,210
Long-term deposits		983	1,832
Deferred tax asset	17	3,063	2,076
Total assets		$375,381	$490,274
Liabilities and shareholders' equity
Current liabilities:
Accounts payable		103	531
Accrued expenses and other liabilities	10	39,581	40,797
Operating lease liabilities, current	18	5,053	5,038
Total current liabilities		44,737	46,366
Non-current liabilities:
Operating lease liabilities, non-current	18	47,914	19,218
Liability related to future royalties and sales milestones, net	11, 23	170,899	125,900
Other long-term payables		357	116
Total liabilities		263,907	191,600
Commitments and contingencies	19
Shareholders' equity:
Ordinary shares, $0.000042 par value; 290,909,783 shares authorized at December 31, 2023 and 2022, 174,101,361 and 173,074,510 shares issued and outstanding at December 31, 2023 and 2022	13	8	8
Deferred shares, £0.00001 par value; 34,425 shares authorized, issued and outstanding at December 31, 2023 and 2022	13	—	—
Deferred B shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at December 31, 2023 and 2022	13	118	118
Deferred C shares, £0.000008 par value; 1 share authorized, issued and outstanding at December 31, 2023 and 2022	13	—	—
Additional paid-in capital		1,018,902	1,007,625
Accumulated other comprehensive loss		(28,992)	(38,898)
Accumulated deficit		(878,562)	(670,179)
Total shareholders' equity		111,474	298,674
Total liabilities and shareholders' equity		$375,381	$490,274

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.